404 related articles for article (PubMed ID: 37284696)
21. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
22. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
23. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
[TBL] [Abstract][Full Text] [Related]
25. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
26. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
27. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
Front Immunol; 2021; 12():733530. PubMed ID: 34659220
[TBL] [Abstract][Full Text] [Related]
28. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
29. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
30. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
32. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
33. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
34. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.
Gordan JD; Keenan BP; Lim HC; Yarchoan M; Kelley RK
Drugs; 2023 Aug; 83(12):1091-1109. PubMed ID: 37402062
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
[TBL] [Abstract][Full Text] [Related]
36. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
38. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.
Lee YR
J Liver Cancer; 2023 Sep; 23(2):316-329. PubMed ID: 37743048
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
Li SQ; Yang Y; Ye LS
World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
Liu TH; Shen YC; Cheng AL
J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
